BioCentury
ARTICLE | Clinical News

Varlilumab: Phase I/II started

March 23, 2015 7:00 AM UTC

Celldex began an open-label, U.S. Phase I/II trial to evaluate 0.1, 1 and 10 mg/kg IV varlilumab every 2 weeks for 24 or 32 weeks plus 3 mg/kg IV Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) in about 190 patients. The Phase II portion will test the dose selected from the dose-escalation Phase I portion in combination with Opdivo in 5 cohorts comprising 18 patients each with colorectal cancer, squamous cell carcinoma of the head and neck (SCCHN) and ovarian cancer and 35 patients each with non-small cell lung cancer (NSCLC) and melanoma. ...